Archaeological research suggests that Cannabis Sativa, the source plant for cannabidiol (CBD) compounds, was one of the first agricultural crops planted by early man near the birth of agriculture some 10,000 to 12,000 years ago. The use of CBD for health benefits extends back several thousand years as well. CBD is one of more than 80 active cannabinoid chemicals in the Cannabis Sativa (marijuana) plant and is a part of the cannabis plant that does not produce euphoria or a “high”. Anecdotally, CBD has long been considered to have a broad range of medical benefits. Now, two major studies released in the last four months have scientifically validated the medicinal efficacy of CBD.
The New England Journal of Medicine just confirmed what thousands have attested to anecdotally for years (http://dtn.fm/0KOsd). The report shows that CBD dramatically reduced the number of convulsive seizures in children with a severe and often fatal epilepsy disorder. “The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with (a) placebo.” The results of the NEJM study follow a sweeping 400-page report released in January by the National Academies of Science, Engineering, and Medicine which covered more than 10,000 scientific studies on marijuana and medicine. The report’s conclusions that marijuana does have legitimate medical uses are supported by scientific studies that show cannabis and cannabinoids are effective at treating chronic pain and that cannabinoid substances were effective for treating chemotherapy-related nausea.
With medical efficacy questions resolved, smart money is now looking for avenues to profit from this explosive new medical market. The Hemp Business Journal (https://www.hempbizjournal.com/) recently projected that the CBD market will grow to a $2.1 billion market in consumer sales by 2020; a 700% increase from 2016 in the U.S. alone. Globally, the growth could be even stronger.
Recently, ChineseInvestors.com (OTCQB: CIIX) has made several interesting announcements highlighting the worldwide growth potential from its investments and commitments in the global cannabis industry. The recent launch of what management identifies as the “world’s first Cannabidiol (CBD) health products online store in the Chinese Language (www.ChineseCBDoil.com)” is a significant milestone for the company and the 2+ billion Chinese speaking people it serves. The company also launched a Chinese language Yelp-style mobile application that contains a location-enabled database of recreational and medical marijuana dispensaries, as well as a platform to review and discuss various cannabis products. ChineseInvestors.com is about to make its mark in the global CBD market.
Historically, ChineseInvestors.com has served as a specialized investment services company providing real-time commentary, analysis, and education-related services in the Chinese language. However, the company’s growth focused, long term quest for value add opportunities led it to stake out a position in the explosive new medical CBD market. With nearly two decades of brand recognition, a current user base of 100,000+ and a target market of nearly two billion Chinese speaking people, ChineseInvestors.com is well positioned to capture more than a fair share of the global Chinese speaking CBD market. Confirming this assumption, SeeThruEquity, a leading independent equity research firm, recently issued an update and increased its price target for CIIX to $3.75, “reflecting potential from the company’s legal cannabis initiatives.” Currently trading near a dollar a share, the upside seems obvious.
For more information, visit the company’s website at www.ChineseInvestors.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
